当前位置: 首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌
编号:13556025
培元固本方抑制肺癌荷瘤小鼠肿瘤生长并延长生存期的实验研究(1)
http://www.100md.com 2019年4月15日 《世界中医药》 20198
     摘要 目的:觀察培元固本方对Lewis肺癌荷瘤小鼠的抑瘤作用及H1299肺癌小鼠生存期的影响。方法:将100只C57BL/6纯系小鼠随机分10组,每组10只。分别是正常组、Lewis肺癌对照组、Lewis肺癌+顺铂组、Lewis肺癌+高剂量组、Lewis肺癌+中剂量组、Lewis肺癌+低剂量组、H1299肺癌对照组、H1299肺癌+高剂量组、H1299肺癌+中剂量组和H1299肺癌+低剂量组。正常组、对照组和顺铂组给予0.2 mL/(只·d)生理盐水,观察组分别给予0.2 mL/(只·d)高、中、低剂量(4.496 g/mL、2.248 g/mL和1.124 g/mL)的培元固本方,连续灌胃15 d。实验结束后,测量Lewis肺癌皮下移植瘤模型小鼠的免疫器官重量、肝肾功能、瘤重和皮下瘤体积并计算抑瘤率,计算H1299肺癌腹水种植瘤模型小鼠生存率,绘制生存曲线图。结果:高、中剂量组的胸腺指数和脾脏指数与荷瘤对照组比较变化不明显(P>0.05),且低剂量组的胸腺指数明显升高(P<0.05),顺铂组的胸腺指数(P<0.01)和脾脏指数(P<0.05)均明显下降;培元固本方组的肝肾功能均正常,顺铂组肝肾功能均不正常,2组患者比较,差异有统计学意义(P<0.01);高、中剂量组的抑瘤率分别为50%和42%,与荷瘤对照组比较瘤重减轻(P<0.05),皮下瘤体积缩小(P<0.05),顺铂组的抑瘤率为73%,与荷瘤对照组和培元固本方组比较,差异有统计学意义(P<0.05);高、中、低剂量组的生命延长率分别为:47%、55.3%和45%,生存期与荷瘤对照组比较明显延长。结论:培元固本方安全无肝肾毒性,且高、中剂量的培元固本方还具有抑制肿瘤生长、提高免疫能力和延长生存期的作用。

    关键词 培元固本方;肺癌;抑瘤作用;生存期;免疫功能

    Abstract Objective:To observe the effect of Peiyuan Guben Decoction on inhibiting tumor growth in mice with Lewis lung cancer and prolonging the survival time in mice with H1299 lung cancer.Methods:A total of 100 C57BL/6 mice were randomly divided into a normal group,a Lewis lung cancer control group,a Lewis lung cancer plus cisplatin group,a Lewis lung cancer plus high-dose group,a Lewis lung cancer plus medium-dose group,a Lewis lung cancer plus low-dose group,a H1299 lung cancer control group,a H1299 lung cancer plus high-dose group,a H1299 lung cancer plus medium-dose group,and a H1299 lung cancer plus low-dose group,with 10 mice in each group.The normal group,control group and cisplatin group were continuously given 0.2 mL per day of normal saline for 15 days,and the treatment groups were respectively intragastric administrated 0.2 mL per day of Peiyuan Guben Decoction at the doses of 4.496 g/mL,2.248 g/mL and 1.124 g/mL.After the trial,the immune organ weight,liver and kidney function,tumor weight and subcutaneous tumor volume were measured and the inhibition rate against tumor in mice with Lewis lung cancer was calculated.Meanwhile,the survival rate was calculated and the survival graph was drawn in mice with H1299 lung cancer.Results:Compared with the control group,the thymus index and spleen index of the high-and medium-dose groups had not significant differences(P>0.05),and the thymus index of the low-dose group was significantly increased(P<0.05).The cisplatin group could significantly decrease the thymus index(P<0.01)and spleen index(P<0.05).The liver and kidney functions of Peiyuan Guben Decoction were normal and the cisplatin group was abnormal,and there were significant differences between them(P<0.01).The high-and medium-dose groups could reduce the tumor weight and the subcutaneous tumor volume compared with the control group(P<0.05),and the tumor inhibition rate was respectively 50% and 42%.The cisplatin group could reduce the tumor weight and the subcutaneous tumor volume,and the tumor inhibition rate was 73%,which was statistically significant compared with the control group and the treatment groups(P<0.05).Peiyuan Guben Decoction could prolong the survival time,and the life extension rates of the high-,medium-and low-dose groups were respectively 47%,55.3% and 45%.Conclusion:Peiyuan Guben Decoction does not have hepatorenal toxicity and is safe.The high dose and medium dose of Peiyuan Guben Decoction could inhibit tumor growth,improve immunity function and prolong the survival time in mice with lung cancer., http://www.100md.com(张素芳 向卉楠 王丽新)
1 2 3 4下一页


    参见:首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌